eligibility_summary
Inclusion: ≥18 with untreated DLBCL or grade 3B FL (incl. composite, transformed, discordant, HGBCL if not for intensive Rx), measurable, ECOG 0–2, ANC≥1000, platelets≥75k, CrCl≥30, bili≤1.5×ULN, AST/ALT≤2.5× (higher if liver), LVEF≥45%, preg test/contraception. Exclusion: recent investigational use, steroids>10 mg/d, immunodeficiency, other active malignancy, CNS mets, ILD/pneumonitis, IV antibiotics, prior transplant, live vaccine<28 d, pregnancy, prior checkpoint Rx, uncontrolled HIV, active HBV/HCV.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase I/II single-arm trial in untreated DLBCL/grade 3B FL/HGBCL evaluates prephase tafasitamab + rituximab + retifanlimab (TRR), then TRR with CHOP or Pola-CHP. Drug types/mechanisms: Tafasitamab—Fc‑engineered anti‑CD19 IgG1 monoclonal antibody (mAb) inducing ADCC/ADCP and apoptosis of B cells. Rituximab (SC with hyaluronidase)—anti‑CD20 IgG1 mAb mediating complement activation and ADCC. Retifanlimab—anti‑PD‑1 checkpoint‑inhibitor mAb restoring T‑cell antitumor activity. CHOP: cyclophosphamide (alkylator/DNA crosslinks), doxorubicin (anthracycline/topo II inhibitor), vincristine (vinca microtubule inhibitor), prednisone (glucocorticoid, lympholytic). Polatuzumab vedotin (optional in place of vincristine)—anti‑CD79b antibody–drug conjugate delivering MMAE (microtubule poison). Targets/pathways: B‑cell antigens CD19, CD20, CD79b, PD‑1 axis on T cells, DNA damage, topoisomerase II, and microtubules.